ACADIA Pharmaceuticals Inc. (ACAD)
NASDAQ: ACAD · Real-Time Price · USD
17.60
+0.44 (2.56%)
May 15, 2025, 4:00 PM - Market closed
ACADIA Pharmaceuticals Stock Forecast
Stock Price Forecast
According to 14 professional analysts, the 12-month price target for ACADIA Pharmaceuticals stock ranges from a low of $20 to a high of $31. The average analyst price target of $24.21 forecasts a 37.56% increase in the stock price over the next year.
Price Target: $24.21 (+37.56%)
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for ACADIA Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 6 | 6 | 5 | 5 | 4 | 4 |
| Buy | 6 | 6 | 6 | 6 | 4 | 4 |
| Hold | 7 | 7 | 8 | 8 | 8 | 7 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 19 | 19 | 19 | 19 | 16 | 15 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $25 → $22 | Strong Buy | Maintains | $25 → $22 | +25.00% | Apr 28, 2025 |
| Needham | Needham | Strong Buy Reiterates $28 | Strong Buy | Reiterates | $28 | +59.09% | Apr 8, 2025 |
| Morgan Stanley | Morgan Stanley | Hold Initiates $20 | Hold | Initiates | $20 | +13.64% | Mar 7, 2025 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Reiterates $28 | Buy | Reiterates | $28 | +59.09% | Feb 27, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $27 | Strong Buy | Reiterates | $27 | +53.41% | Feb 27, 2025 |
Financial Forecast
Revenue This Year
1.09B
from 957.80M
Increased by 13.49%
Revenue Next Year
1.20B
from 1.09B
Increased by 10.49%
EPS This Year
0.66
from 1.36
Decreased by -51.34%
EPS Next Year
1.00
from 0.66
Increased by 51.47%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.1B | 1.4B | 1.6B | ||
| Avg | 1.1B | 1.2B | 1.3B | ||
| Low | 1.0B | 1.1B | 1.2B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 19.4% | 28.2% | 32.1% | ||
| Avg | 13.5% | 10.5% | 10.3% | ||
| Low | 7.4% | 1.0% | -3.7% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 1.40 | 1.97 | 2.50 | ||
| Avg | 0.66 | 1.00 | 1.45 | ||
| Low | 0.08 | 0.33 | 0.89 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 2.7% | 198.3% | 149.3% | ||
| Avg | -51.3% | 51.5% | 44.7% | ||
| Low | -94.2% | -49.7% | -11.0% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.